Skip to Content
Merck
CN

L9044

LY2183240

≥98% (HPLC)

Synonym(s):

1H-Tetrazole-1-carboxamide, 5-([1,1′-biphenyl]-4-ylmethyl)-N,N-dimethyl-, 5-Biphenyl-4-ylmethyl-tetrazole-1-carboxylic acid dimethylamide

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C17H17N5O
CAS Number:
Molecular Weight:
307.35
UNSPSC Code:
12352200
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

≥98% (HPLC)

drug control

Új pszichoaktív anyag / New psychoactive substance (Hungary), 78/2022. (XII. 28.) BM rendelet

storage condition

desiccated

solubility

DMSO: >10 mg/mL

storage temp.

2-8°C

SMILES string

CN(C)C(=O)n1nnnc1Cc2ccc(cc2)-c3ccccc3

Biochem/physiol Actions

Regioisomer 1-5 of LY2183240 is a potent inhibitor of anandamide uptake (IC50= 15 nM).
Regioisomer 1-5 of LY2183240 is a potent inhibitor of anandamide uptake (IC50= 15 nM). The compound inhibits FAAH (IC50=2.1 nM) and some other brain serine proteases. After systemic administration to rodents, LY2182340 elevates brain anandamide levels and shows efficacy in a rodent model of persistent pain (ED50=1.37 mg/kg). Regioisomer 2-5 of LY2183240 is less active. The compound is more potent than N-(4-Hydroxyphenyl)-arachidonylamide (AM-404), which inhibits anandamide transport at IC50=1mM.


pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Simon Nicolussi et al.
Biochemical pharmacology, 92(4), 669-689 (2014-10-07)
Besides the suggested role of a putative endocannabinoid membrane transporter mediating the cellular uptake of the endocannabinoid anandamide (AEA), this process is intrinsically coupled to AEA degradation by the fatty acid amide hydrolase (FAAH). Differential blockage of each mechanism is